Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial
Fig 3
Variation over time of immunophenotype in two groups of HIV-1-infected patients starting their first antiretroviral treatment at different baseline CD4+ T-cell counts (late presenters [grey line] ≤200 cells/μL; early presenters [black line] >200 cells/μL).
Medians and interquartile ranges are shown.